Insulin resistance - The new goal!

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 3, 2003, Pages 167-174

  Peter, P ^a   Nuttall, S L ^a   Kendall, M J ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Insulin resistance; Thiazolidinediones

Indexed keywords

METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; THIAZOLIDINE DERIVATIVE;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; REVIEW; UNITED KINGDOM;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037803500     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00482.x     Document Type: Review

References (45)

1. Amos AF, Mc Carthy DJ, Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine, 14, 81-85.
2. Pan WH, Cedres LB, Liu K et al. (1986) Relationship of clinical diabetes and asymptomatic hyperglycaemia to risk of coronary heart disease mortality in men and women. American Journal of Epidemiology, 123, 504-516.
3. Stamler J, Vaccaro O, Neaton JD (1993) Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16, 434-444.
4. Malmberg K, Yusuf S, Gerstein HC et al. (2000) Organisation to assess strategies for ischemic syndromes. OASIS study. Circulation, 102, 1014-1019.
5. Miettinen H, Lehto S, Salimoa V et al. (1998) Impact of diabetes on mortality after 1st MI. The Finmonica Myocardial Infarction Register study group. Diabetes Care, 21, 69-75.
6. Gu K, Cowie CC, Harris MI (1999) Changes in CaD Mortality (NHANES study). Journal of the American Medical Association, 281, 1291-1297.
7. Haffner SM, Lehto S, Ronnemma T (1998) Mortality from CHD in subjects with type 2 diabetes and in non-diabetics with or without prior myocardial infarction. New England Journal of Medicine, 339, 229-234.
8. United Kingdom Prospective Study Group. UKPDS VIII (1991) Study design, progress and performance. Diabetologia, 34, 877-890.
9. Hales CN, Baker DJ (1992) Type 2 diabetes: the thrifty phenotype hypothesis. Diabetologia, 35, 595-601.
10. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
11. Mills JD, Grant PJ (2002) Insulin resistance, haemostatic factors and cardiovascular risk. British Journal of Diabetes and Vascular Disease, 2, 19-23.
12. Hollenbeck C, Reaven GM (1987) Variation in insulin estimated glucose uptake in healthy individuals with normal glucose tolerance. Journal of Clinical Endocrinology and Metabolism, 64, 1169-1173.
13. Turner NC, Clapham JC (1998) Insulin resistance, impaired glucose tolerance and non-insulin dependent diabetes mellitus - pathologic mechanisms and treatment: current status and therapeutic possibilities. Progress in Drug Research, 51, 36-94.
14. Ukkola D, Bouchard C (2001) Clustering of metabolic abnormalities in obese individuals: the role of genetic factors. American Journal of Medicine, 33, 79-90.
15. Laakso M (2002) Insulin resistance and cardiovascular disease. British Journal of Diabetes and Vascular Disease, 2(suppl. 1), S9-S11.
16. Bjorntorp P (1991) Metabolic implications of body fat distribution. Diabetes Care, 14, 1132-1143.
17. Meigs JB, Mettlean MA, Nathan DM et al. (2000) Hyperinsulinaemia, hyperglycaemia and impaired haemostasis: The Framingham Offspring Study. Journal of the American Medical Association, 283, 221-228.
18. Reaven GM (1996) Insulin resistance and its consequences: non-insulin dependent diabetes mellitus. Philadelphia: Lippin-Cott Raven, 509-519.
19. Mansfield MW, Steikland MH, Grant PJ (1997) PAI concentration in first degree relatives of patients with non-insulin dependant diabetes mellitus: metabolic and genetic associations. Thrombosis and Haemostasis, 77, 357-361.
20. Juhan-Vague I, Pyke SDM, Alessi MC et al. (1996) Fibrinolytic factors and the risk of MI or sudden death in patients with angina pectoris. Circulation, 94, 2057-2063.
21. Mansfield MW, Heywood DM, Grant PJ (1996) Circulating levels of factor VII, fibrinogen and von Willebrand factor and features of insulin resistance in first degree relatives of patients with NIDDM. Circulation, 94, 2171-2176.
22. Heywood DM, Mansfield MW, Grant PJ (1996) Factor VII gene polymerisms, factor VII: C levels and features of insulin resistance in non-insulin dependent diabetes mellitus. Thrombosis and Haemostasis, 75, 401-406.
23. Miller GJ, Esnouf MP, Burgess AI (1997) Risk of coronary heart disease and activation of factor XII in middle aged men. Arteriosclerosis, Thrombosis and Vascular Biology, 17, 2103-2106.
24. Yudkin JS, Kumari M, Humphries SE et al. (2000) Inflammation, obesity, stress and CHD. Is interleukin-6 the link? Atherosclerosis, 148, 209-214.
25. Ganda OP, Arka CF (1992) Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care, 15, 1245-1250.
26. Yudkin JS (1999) Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence of a common antecedant? Diabetes Care, 22 (Suppl 3), C25-C30.
27. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidative stress. Circulation Research, 87, 840-844.
28. Savers J, Savers P, Peuler J (1994) Role of insulin resistance and hyperinsulinaemia in development of hypertension and atherosclerosis. Journal of Laboratory and Clinical Medicine, 123, 647-652.
29. Agewall S (1999) Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk. Journal of Internal Medicine, 246, 489-495.
30. Cantin B, Despres JP, Lamarche B et al. (2002) Quebec cardiovascular study group. Association of fibrinogen and lipoprotein A as coronary heart disease risk factors in men. American Journal of Cardiology, 89, 662-666.
31. Lehto S, Ronnemma T, Pyorolla K et al. (2000) Cardiovascular risk factor clustering with endogenous hyperinsulinaemia predicts death from coronary heart disease in patients with type 2 DM. Diabetologia, 43, 148-155.
32. Wilson TM, Brown PJ, Sternbach DD et al. (2000) The PPAR's- from orphan receptors to drug discovery. Journal of Clinical Medicine, 43, 527-550.
33. Schoonjans K, Staus B, Auverx J (1996) Role of peroxisome proliferator activated receptors in mediating the effect of fibrates and fatty acids on gene expression. Journal of Lipid Research, 37, 907-925.
34. Rosen ED, Spiegelman BM (2001) PPAR γ- a nuclear regulator of metabolism, differentiation and cell growth. Journal of Biological Chemistry, 276, 3731-3734.
35. Hayakawa T, Shiraki T, Morimoto T et al. (1996) Pioglitazone improves insulin signalling defects in skeletal muscle from fatty rats. Biochemical and Biophysical Research Communications, 129, 439-444.
36. Smith U, Gogg S, Johansson A et al. (2001) Thiazolidinediones (PPAR γ agonists and not PPARα agonists) increase IRS-2 gene expression in 3T3-L1 and human adipocytes. Federation of American Societies for Experimental Biology, FASEB J, 15, 215-220.
37. Chinetti G, Fruchart JC, Staels B (2000) Peroxisome proliferator activated receptors: nuclear receptors at the cross roads between lipid metabolism and inflammation. Inflammation Research, 49, 497-505.
38. Lebovitz HE, Banerji MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Progress in Hormonal Research, 56, 265-294.
39. Parulkar A, Pendergrans ML, Grand-Ayala R et al. (2001) Non hypoglycemic effects of thiazolidinediones. Annals of Internal Medicine, 134, 61-71.
40. Bailey CJ, Day C (2001) Thiazolidinediones today. British Journal of Diabetes and Vascular Disease, 1, 7-13.
41. Hansfield M, Goke B (2000) Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes. Experimental Clinical Endocrinology and Diabetes, 108, S256-S266.
42. Schneider R, Egan J, Houser V (1999) Combination therapy with pioglitazone and sulphonylureas in patients with type 2 diabetes. Diabetes, 48(suppl 1), A458.
43. Rosenstock J (2000) Impaired insulin sensitivity and beta cell responsivity suggested by HOMA analyses of pioglitazone therapy. Diabetologia, 43, A-192-abstract 738.
44. Matheson A, Egan J, Schneider R (1999) Pioglitazone 010 study group. The effect of combination therapy with pioglitazone and sulfonylurea in the lipid profile in patients with type 2 diabetes. Diabetes, 48 (suppl 1), A-106.
45. Parulkar AA, Pendergrass ML, Grand-Ayala R, Lee TR, Fonseca VA (2001) Non hypoglycemic effects of Thiazolidinediones. Annals of Internal Medicine, 134, 61-71.